169 related articles for article (PubMed ID: 12389615)
1. B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseases.
Nardelli B; Moore PA; Li Y; Hilbert DM
Leuk Lymphoma; 2002 Jul; 43(7):1367-73. PubMed ID: 12389615
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of BLyS action in B cell immunity.
Do RK; Chen-Kiang S
Cytokine Growth Factor Rev; 2002 Feb; 13(1):19-25. PubMed ID: 11750877
[TBL] [Abstract][Full Text] [Related]
3. Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity.
Yan M; Marsters SA; Grewal IS; Wang H; Ashkenazi A; Dixit VM
Nat Immunol; 2000 Jul; 1(1):37-41. PubMed ID: 10881172
[TBL] [Abstract][Full Text] [Related]
4. B lymphocytes from individuals with common variable immunodeficiency respond to B lymphocyte stimulator (BLyS protein) in vitro.
Stewart DM; McAvoy MJ; Hilbert DM; Nelson DL
Clin Immunol; 2003 Nov; 109(2):137-43. PubMed ID: 14597212
[TBL] [Abstract][Full Text] [Related]
5. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator.
Moore PA; Belvedere O; Orr A; Pieri K; LaFleur DW; Feng P; Soppet D; Charters M; Gentz R; Parmelee D; Li Y; Galperina O; Giri J; Roschke V; Nardelli B; Carrell J; Sosnovtseva S; Greenfield W; Ruben SM; Olsen HS; Fikes J; Hilbert DM
Science; 1999 Jul; 285(5425):260-3. PubMed ID: 10398604
[TBL] [Abstract][Full Text] [Related]
6. Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors.
Jelinek DF; Darce JR
Curr Dir Autoimmun; 2005; 8():266-88. PubMed ID: 15564725
[TBL] [Abstract][Full Text] [Related]
7. To B or not to B: TNF family signaling in lymphocytes.
Siegel RM; Lenardo MJ
Nat Immunol; 2001 Jul; 2(7):577-8. PubMed ID: 11429537
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response.
Do RK; Hatada E; Lee H; Tourigny MR; Hilbert D; Chen-Kiang S
J Exp Med; 2000 Oct; 192(7):953-64. PubMed ID: 11015437
[TBL] [Abstract][Full Text] [Related]
9. Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice.
Riccobene TA; Miceli RC; Lincoln C; Knight Y; Meadows J; Stabin MG; Sung C
J Nucl Med; 2003 Mar; 44(3):422-33. PubMed ID: 12621010
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency.
Yan M; Brady JR; Chan B; Lee WP; Hsu B; Harless S; Cancro M; Grewal IS; Dixit VM
Curr Biol; 2001 Oct; 11(19):1547-52. PubMed ID: 11591325
[TBL] [Abstract][Full Text] [Related]
11. BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists.
Stohl W
Curr Dir Autoimmun; 2005; 8():289-304. PubMed ID: 15564726
[TBL] [Abstract][Full Text] [Related]
12. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator.
Baker KP; Edwards BM; Main SH; Choi GH; Wager RE; Halpern WG; Lappin PB; Riccobene T; Abramian D; Sekut L; Sturm B; Poortman C; Minter RR; Dobson CL; Williams E; Carmen S; Smith R; Roschke V; Hilbert DM; Vaughan TJ; Albert VR
Arthritis Rheum; 2003 Nov; 48(11):3253-65. PubMed ID: 14613291
[TBL] [Abstract][Full Text] [Related]
13. The role of BLyS/BLyS receptors in anti-chromatin B cell regulation.
Hondowicz BD; Alexander ST; Quinn WJ; Pagán AJ; Metzgar MH; Cancro MP; Erikson J
Int Immunol; 2007 Apr; 19(4):465-75. PubMed ID: 17369193
[TBL] [Abstract][Full Text] [Related]
14. Activation and accumulation of B cells in TACI-deficient mice.
Yan M; Wang H; Chan B; Roose-Girma M; Erickson S; Baker T; Tumas D; Grewal IS; Dixit VM
Nat Immunol; 2001 Jul; 2(7):638-43. PubMed ID: 11429549
[TBL] [Abstract][Full Text] [Related]
15. Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI.
Liu W; Szalai A; Zhao L; Liu D; Martin F; Kimberly RP; Zhou T; Carter RH
Arthritis Rheum; 2004 Jun; 50(6):1884-96. PubMed ID: 15188365
[TBL] [Abstract][Full Text] [Related]
16. Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers.
Harless SM; Lentz VM; Sah AP; Hsu BL; Clise-Dwyer K; Hilbert DM; Hayes CE; Cancro MP
Curr Biol; 2001 Dec; 11(24):1986-9. PubMed ID: 11747827
[TBL] [Abstract][Full Text] [Related]
17. The BLyS family of ligands and receptors: an archetype for niche-specific homeostatic regulation.
Cancro MP
Immunol Rev; 2004 Dec; 202():237-49. PubMed ID: 15546397
[TBL] [Abstract][Full Text] [Related]
18. Integrating B cell homeostasis and selection with BLyS.
Harless Smith S; Cancro MP
Arch Immunol Ther Exp (Warsz); 2003; 51(4):209-18. PubMed ID: 12956429
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival.
Novak AJ; Bram RJ; Kay NE; Jelinek DF
Blood; 2002 Oct; 100(8):2973-9. PubMed ID: 12351410
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and release of B-lymphocyte stimulator from myeloid cells.
Nardelli B; Belvedere O; Roschke V; Moore PA; Olsen HS; Migone TS; Sosnovtseva S; Carrell JA; Feng P; Giri JG; Hilbert DM
Blood; 2001 Jan; 97(1):198-204. PubMed ID: 11133761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
